On July 30, 2024, Heartseed Inc., a portfolio company of the MIJ No.2 Fund, was listed on the Tokyo Stock Exchange Growth Market. Heartseed is focused on commercializing remuscularization, a myocardial replacement therapy that involves the direct injection of cardiomyocytes into the heart. These cells are differentiated, mass-cultured, and purified from iPS cells using the company’s proprietary technology. This technology is currently in clinical trials and is expected to see accelerated development following the listing.